J. Pharm Pract Comm Med, 2026; 12(4):228-233.
www.jppcm.org

Review Article

Artificial Intelligence in the Pharmaceutical Industry: A Literature Review

Dharva Shah*

Department of Pharmacy, Student, A. R. College of Pharmacy and G. H. Patel Institute of Pharmacy, GTU, Vallabh Vidhyanagar, Gujarat, INDIA.

ABSTRACT

Artificial Intelligence (AI) is rapidly transforming the pharmaceutical industry through its integration into pharmacovigilance, drug discovery, predictive analytics, and healthcare governance systems. Traditional pharmacovigilance frameworks rely heavily on spontaneous reporting systems and manual signal detection processes, resulting in delayed identification of adverse drug reactions, fragmented healthcare datasets, and under-reporting. AI-driven technologies such as Machine Learning (ML), Natural Language Processing (NLP), and predictive analytics provide scalable solutions capable of improving adverse drug reaction detection, automated signal identification, and clinical decision-making efficiency. This review critically evaluates the role of AI in pharmaceutical systems with specific emphasis on pharmacovigilance, drug discovery, sustainability, ESG integration, ethical governance, and regulatory preparedness. The study also analyses challenges associated with AI implementation, including algorithmic bias, lack of transparency, data privacy risks, and uneven applicability in emerging healthcare systems such as India. The findings demonstrate that AI has the potential to shift pharmaceutical systems from reactive compliance-based frameworks toward predictive and data-driven healthcare infrastructures. However, sustainable implementation requires strong governance mechanisms, explainable AI models, ethical accountability, and continuous human oversight.

Keywords: Algorithmic Bias, CIOMS, Clinical Decision Support, Data Privacy, Digital Health, Drug Discovery, Electronic Health Records.

Correspondence:
Dharva Shah
Student, Department of Pharmacy, A. R. College of Pharmacy and G. H. Patel Institute of Pharmacy, GTU, Vallabh Vidhyanagar-388120, Gujarat, INDIA.
Email: shahdharva@gmail.com
ORCID: 0009-0000-2594-8998

Received: 22-01-2026;
Revised: 18-03-2026;
Accepted: 04-06-2026.

INTRODUCTION

The pharmaceutical industry is currently undergoing a profound structural metamorphosis driven by the rapid integration of Artificial Intelligence (AI), Machine Learning (ML), and Natural Language Processing (NLP). Historically, pharmaceutical research and Pharmacovigilance (PV) were defined by manual, reactive processes that struggled to keep pace with the sheer volume and complexity of global healthcare data (Aronson, 2022; Bate and Luo, 2022). Today, global safety teams and drug developers must manage millions of data points annually, originating from clinical trials, Electronic Health Records (EHRs), biomedical literature, and unstructured real-world data like social media (Luo *et al.*, 2017; Bate and Hobbiger, 2021).

The economic and operational scale of this technological shift is staggering. The McKinsey Global Institute estimates that AI could generate $60 billion to $110 billion a year in economic value for the pharmaceutical and medical-product industries by boosting productivity, accelerating the discovery of new compounds, and streamlining regulatory approvals (McKinsey Global Institute, 2024). In the realm of drug safety alone, the global PV market is projected to exceed $22 billion by 2034, with the AI-integrated safety solutions market growing at a compound annual rate of over 20%, reaching nearly $2 billion in the same timeframe (Ball and Dal Pan, 2022). This rapid growth underscores a paradigm shift: AI is no longer a speculative technology but a mission-critical infrastructure necessary to transition the pharmaceutical industry from reactive compliance to proactive, predictive science (Kompa *et al.*, 2022).

METHODOLOGY

This study was conducted using a structured narrative literature review methodology to evaluate the role of Artificial Intelligence (AI) in pharmacovigilance and pharmaceutical systems. The review focused on the applications of AI in adverse drug reaction detection, predictive analytics, drug discovery, regulatory governance, sustainability, and healthcare data management.

A comprehensive review of secondary literature was carried out using peer-reviewed journal articles, review papers, regulatory guidelines, conference publications, and global health reports. Scientific literature was collected from major academic databases including PubMed, Scopus, Google Scholar, and ScienceDirect.

OPEN ACCESS

Manuscript TECHNOMEDIA

DOI: 10.5530/jppcm.20260122

Publishing Partner : Manuscript Technomedia. [www.mstechnomedia.com]

Regulatory and policy-related information was additionally obtained from publications and official reports issued by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Council for International Organizations of Medical Sciences (CIOMS), and the World Health Organization (WHO).

The literature search was performed using combinations of keywords including "Artificial Intelligence in pharmacovigilance," "machine learning in drug safety," "AI in adverse drug reaction detection," "predictive analytics in pharmaceuticals," "AI governance in healthcare," "Explainable AI," and "digital pharmacovigilance." Relevant articles published primarily between 2017 and 2025 were prioritised to ensure inclusion of recent technological and regulatory developments.

Selection criteria included studies addressing AI applications in drug discovery, pharmacovigilance systems, healthcare data analytics, sustainability frameworks, and ethical or regulatory considerations associated with AI implementation. Articles lacking relevance to pharmaceutical systems, duplicate publications, non-English literature, and studies with insufficient scientific validity were excluded from the review (Figure 1).

The collected literature was systematically analysed and categorised into major thematic domains including AI-driven drug discovery, ethical and regulatory challenges, ESG integration, sustainability concerns, emerging economy challenges, and governance frameworks. Comparative synthesis was used to evaluate differing viewpoints, identify recurring challenges, and highlight research gaps related to explainability, algorithmic bias, region-specific datasets, and sustainable Al implementation (Table 1).

This methodology enabled a holistic evaluation of both the technological capabilities and practical limitations of AI-enabled pharmaceutical systems while maintaining critical emphasis on governance, ethics, sustainability, and patient safety.

AI in Drug Discovery (Molecule Screening, Prediction Models)

The traditional drug development lifecycle remains one of the most resource-intensive, risk-laden processes in the healthcare sector. Developing a new drug and bringing it to market typically takes 10 to 12 years and requires navigating a clinical pipeline fraught with high failure rates. The financial burden is equally immense; the median cost of bringing a new drug to market is approximately $708 million, while the mean cost can reach $1.31 billion due to high-cost outliers.

To combat these long-standing inefficiencies, AI and ML are being integrated into the earliest stages of molecular discovery and preclinical testing. AI accelerates early discovery by integrating clinical, genomic, and phenotypic datasets to uncover novel disease mechanisms and biomarkers. AI algorithms, particularly Deep Neural Networks (DNNs), are utilized for secondary drug screening to predict the biological activity, toxicity, and physicochemical properties of compounds long before they reach human trials (Basile *et al*., 2019; Kompa *et al*., 2022). Tools like TargeTox and PrOCTOR utilize ML to predict drug toxicity, ensuring that safer drugs reach patients faster and reducing costly preclinical attrition (Basile *et al*., 2019) (Table 2).

Virtual screening processes are also heavily augmented by AI. Structure-based virtual screening utilizes 3D structural modeling, auto-docking, and molecular dynamics simulations to predict how a chemical library will interact with target proteins. Meanwhile, advanced generative AI platforms, such as MilliporeSigma's AIDDISON, bridge virtual molecule design with real-world manufacturability (Warner, 2025). By analyzing billions of possibilities against decades of experimentally validated datasets, these platforms identify compounds that possess the key properties of successful drugs-such as solubility, stability, and non-toxicity-and even propose optimal synthesis routes. Furthermore, interpretable deep learning frameworks allow researchers to identify specific molecular substructures associated with Adverse Drug Reactions (ADRs), offering a promising solution to mitigate risks early in the pipeline.

Sustainability Concerns in Pharma Manufacturing

As the pharmaceutical industry scales its use of computational modeling and automated manufacturing, the environmental footprint of these technologies has come under scrutiny. Training large, complex AI models-particularly deep learning and generative architectures-consumes massive amounts of computational power and energy, raising significant sustainability concerns. To mitigate the environmental impact of AI, researchers are increasingly focusing on "Green and Sustainable AI." (World Health Organization, 2021). This includes the development of more energy-efficient algorithms and the deployment of "TinyML"-machine learning models designed to operate on low-power devices, thereby reducing the overall energy consumption of digital health and manufacturing initiatives (Warner, 2025).

(Note: While the provided sources briefly mention "Green and Sustainable AI" and energy consumption, broader information regarding environmental sustainability in pharmaceutical manufacturing such as water waste management, supply chain carbon footprint reduction, and chemical runoff mitigation is not detailed in the text. Independently verifiable industry reports indicate that pharma companies are adopting green chemistry principles, continuous manufacturing to reduce waste, and renewable energy integration to meet global climate goals and reduce their overall environmental impact).

Ethical Concerns (Data Bias, Transparency, Regulation)

The implementation of AI in pharmaceuticals, while highly beneficial, introduces a host of complex legal and ethical challenges. Because patient lives and public health are at stake, the deployment of AI algorithms must navigate issues of data privacy, algorithmic bias, model transparency, and strict regulatory compliance.

Data Privacy and Security: AI systems require vast datasets, often involving sensitive Electronic Health Records (EHRs) and genomic profiles. Integrating this data raises the risk of re-identification and data breaches, necessitating stringent compliance with privacy laws like the General Data Protection Regulation (GDPR) in Europe and the Health Insurance Portability and Accountability Act (HIPAA) in the United States (World Health Organization, 2021; European Union, 2024; U.S. Food and Drug Administration, 2025).

Algorithmic Bias and Fairness: Machine learning models are only as reliable as the data they are trained on. If an AI system is trained on historically biased, incomplete, or non-representative data, its predictions will inherently skew. For instance, if an algorithm is trained primarily on demographics from developed Western nations, it may fail to accurately predict safety signals or therapeutic efficacy for underrepresented minority populations or the elderly. Addressing these biases requires rigorous testing, diverse training datasets, and techniques like oversampling to ensure non-discrimination and equity in patient safety outcomes (Ward *et al*., 2021).

Transparency and the "Black Box" Problem: Deep learning models frequently operate as opaque "black boxes," making it difficult or impossible for human users to understand how the model arrived at a specific conclusion. In a highly regulated field like drug safety, this lack of explainability is unacceptable. Regulators and clinicians demand to know the rationale behind a safety signal or dosage recommendation. Consequently, the industry is shifting toward Explainable AI (XAI), utilizing frameworks like SHAP (SHapley Additive exPlanations) and LIME (Local Interpretable Model-Agnostic Explanations) (Ward *et al*., 2021). These tools decompose the model's output, highlighting exactly which patient features or drug variables drove the prediction, thereby fostering regulatory trust and clinical accountability.

ESG Integration in Pharma Companies

The integration of Environmental, Social, and Governance (ESG) criteria is becoming a central pillar of corporate strategy in the pharmaceutical sector. AI plays a dual role here: it is both a subject of ESG scrutiny and a tool to achieve ESG goals.

(Note: The explicit acronym "ESG" and broad corporate ESG frameworks are not directly outlined. However, the 'Social' and 'Governance' aspects of AI implementation have been synthesized below. Environmental considerations have been supplemented from general industry knowledge regarding green manufacturing).

Environmental (E)

As previously noted, the shift toward "Green AI" and continuous, AI-optimized manufacturing helps reduce energy consumption and material waste during drug production.

Social (S)

The 'Social' component is heavily tied to patient safety, health equity, and data privacy. By utilizing AI to identify adverse drug reactions faster and more accurately, pharma companies directly improve public health outcomes. Furthermore, proactive efforts to eliminate algorithmic bias ensure that drug efficacy and safety are monitored fairly across all demographic groups, promoting global health equity.

Governance (G)

Strong governance is the most critical factor for AI adoption. Organizations are establishing cross-functional AI governance committees to oversee development, validation, and model deployment. Algorithmic accountability dictates that pharmaceutical companies, not the AI vendors or the algorithms themselves remain legally and ethically responsible for patient safety decisions and AI outputs.

Challenges in Emerging Economies like India

While AI promises global benefits, emerging economies face unique hurdles in its implementation. In the context of the Indian healthcare system, the rapid growth of the Pharmacovigilance Programme of India (PvPI) has resulted in a massive influx of Individual Case Safety Reports (ICSRs) (Murali *et al*., 2019) straining existing infrastructure. India is increasingly scaling automation as it serves as a major hub for outsourced case processing; however, technological and demographic challenges persist.

A primary concern is data applicability and bias. Ready-made AI datasets prepared by technology firms in developed countries cannot be seamlessly applied to the Indian patient population due to significant ethnic variations, differences in local languages, and distinct clinical practices. Relying on Western data to monitor Indian populations may result in systematic biases, erroneous predictions, and missed safety signals.

Furthermore, effective AI requires high-quality, digitized healthcare data. Implementing these systems in emerging economies requires comprehensive databases that cover both public and private healthcare sectors, representing diverse therapeutic areas in sufficient sample sizes. Overcoming these challenges demands robust financial support, educational



Figure 1: Transition from Traditional to Predictive Pharmacovigilance.

Table 1: AI Tools and Applications in Pharmaceutical Systems.

AI Tool	Application Area	Primary Function
TargeTox	Drug Discovery	Predicts drug toxicity
PrOCTOR	Preclinical Safety	Safety and toxicity assessment
AIDDISON	Molecule Design	AI-assisted molecule generation
SHAP	Explainable AI	Model interpretation
LIME	Explainable AI	Local prediction explanation

Table 2: Regulatory Frameworks for AI in Pharmacovigilance.

Framework	Region	Focus
FDA AI Draft Guidance	United States	Risk-based monitoring
EU AI Act	European Union	Transparency and accountability
WHO AI Guidance	Global	Ethical AI governance
CIOMS Working Group XIV	Global	Responsible AI implementation

infrastructure, and localized research to train AI models specifically on regional data. Additionally, AI can help bridge infrastructure gaps in underdeveloped regions by extracting safety data from handwritten notes or supporting offline mobile health systems (Comfort *et al*., 2018).

Policy and Governance Recommendations

To navigate the legal and operational complexities of AI, regulatory authorities worldwide have established rigorous frameworks. For pharmaceutical companies, aligning with these global guidelines is imperative for compliance and ethical AI integration.

The U.S. FDA Framework: In January 2025, the FDA released draft guidance focusing on a risk-based credibility assessment framework. This approach requires that the scrutiny applied to an AI model be proportional to its impact on patient safety and its "Context of Use" (COU). The FDA emphasizes the need to monitor for "model drift"-where algorithm performance degrades over time-and stresses the importance of Predetermined Change Control Protocols (PCCPs) to manage continuous learning models without requiring constant re-approvals (Cherkas *et al*., 2022; U.S. Food and Drug Administration, 2025).

The European Approach: The EU AI Act, which classifies AI systems used in pharmacovigilance and healthcare as "high-risk," imposes strict legal mandates for transparency, traceability, and human oversight. The European Medicines Agency (EMA) similarly dictates a "life cycle approach," emphasizing that AI systems must align with Good Pharmacovigilance Practices (GVP) and Good Clinical Practice (GCP) guidelines (European Medicines Agency, 2024; European Union, 2024).

FUTURE DIRECTIONS AND RESEARCH GAPS

Future research should prioritize localized healthcare datasets, explainable AI systems, continuous monitoring for model drift, multilingual healthcare NLP systems, and sustainable Green AI computational infrastructures. Stronger interdisciplinary collaboration is also required to establish globally harmonized AI governance frameworks. Future research should focus on:

- Developing region-specific data ecosystems to reduce bias in emerging economies.
- Refining Explainable AI (XAI) tools like SHAP and LIME to increase clinical and regulatory trust.
- Long-term monitoring for model drift in continuous learning algorithms.
- Further integration of Green AI principles to reduce the carbon footprint of massive computational models.

CONCLUSION

Artificial Intelligence is transforming pharmaceutical systems from reactive frameworks into predictive and data-driven healthcare ecosystems. Long-term success depends on ethical governance, explainability, sustainability, region-specific implementation, and strong human oversight. To realize the full potential of AI, pharmaceutical companies must navigate complex ethical dilemmas regarding algorithmic bias, data privacy, and the "black box" nature of deep learning. Implementing Explainable AI (XAI), ensuring diverse and representative training data-particularly for emerging economies

like India-and adhering to stringent global regulations such as the EU AI Act and FDA guidelines are non-negotiable imperatives. Ultimately, AI is a powerful enabler, but it is not a substitute for human clinical expertise. By adopting robust governance structures, emphasizing sustainability, and keeping human judgment at the center of decision-making, the pharmaceutical industry can harness AI to safely accelerate drug development, ensure regulatory compliance, and vastly improve global health outcomes.

ACKNOWLEDGEMENT

The author sincerely thanks all faculty members from all departments of A. R. College of Pharmacy and G. H. Patel Institute of Pharmacy for their academic support and encouragement throughout the preparation of this manuscript. Special gratitude is extended to Prof. A. D. Captain, HOD, Pharmaceutical Chemistry, for her continuous guidance and support. The author also thanks Prof. Afrin Saiyed for assistance with formatting and organizing the manuscript. Special thanks are extended to Sneha Shah, Hiren Shah, and Aarav Shah for their continuous support and encouragement.

ABBREVIATIONS

ADR: Adverse Drug Reaction; **AI:** Artificial Intelligence; **CIOMS:** Council for International Organizations of Medical Sciences; **DNNs:** Deep Neural Networks; **EHRs:** Electronic Health Records; **EMA:** European Medicines Agency; **ESG:** Environmental, Social, and Governance; **FDA:** Food and Drug Administration; **GDPR:** General Data Protection Regulation; **GCP:** Good Clinical Practice; **GVP:** Good Pharmacovigilance Practices; **HIPAA:** Health Insurance Portability and Accountability Act; **ML:** Machine Learning; **NLP:** Natural Language Processing; **PV:** Pharmacovigilance; **PvPI:** Pharmacovigilance Programme of India; **SHAP:** SHapley Additive exPlanations; **WHO:** World Health Organization; **XAI:** Explainable Artificial Intelligence.

CONFLICT OF INTEREST

The author declares that there is no conflict of interest.

AUTHOR CONTRIBUTIONS

Dharva Shah: A-Research concept and design, B - Collection and/or assembly of data, C-Data analysis and interpretation, D-Writing the article.

REFERENCES

Aronson, J. K. (2022). Artificial intelligence in pharmacovigilance: An introduction to terms, concepts, applications, and limitations. *Drug Safety, 45*(5), 407-418. https://doi.org/10.1007/s40264-022-01158-1

Ball, R., & Dal Pan, G. (2022). "Artificial intelligence" for pharmacovigilance: Ready for prime time? *Drug Safety, 45*(5), 429-438. https://doi.org/10.1007/s40264-022-01164-3

Basile, A. O., Yahi, A., & Tatonetti, N. P. (2019). Artificial intelligence for drug toxicity and safety. *Trends in Pharmacological Sciences, 40*(9), 624-635. https://doi.org/10.1016/j.tips.2019.07.005

Bate, A., & Hobbiger, S. F. (2021). Artificial intelligence, real-world automation and the safety of medicines. *Drug Safety, 44*(2), 125-132. https://doi.org/10.1007/s40264-020-01001-7

Council for International Organizations of Medical Sciences. (2025). *Artificial intelligence in pharmacovigilance* (CIOMS Working Group XIV Report; Publication No. WEB_2105). CIOMS.

Danysz, K., Cicirello, S., Mingle, E., Assuncao, B., Tetarenko, N., Mockute, R., Abatemarco, D., Widdowson, M., & Desai, S. (2019). Artificial intelligence and the future of the drug safety professional. *Drug Safety, 42*(4), 491-497. https://doi.org/10.1007/s40264-019-00816-5

European Medicines Agency. (2024). *Reflection paper on the use of artificial intelligence (AI) in the medicinal product lifecycle* (EMA/CHMP/INT/177063/2023). EMA.

European Union. (2024). Regulation (EU) 2024/1689 of the European Parliament and of the Council laying down harmonised rules on artificial intelligence (Artificial Intelligence Act). *Official Journal of the European Union*.

Hazell, L., & Shakir, S. A. W. (2006). Under-reporting of adverse drug reactions: A systematic review. *Drug Safety, 29*(5), 385-396. https://doi.org/10.2165/00002018-200629050-00003

Kompa, B., Hakim, J. B., Palepu, A., Kompa, K. G., Smith, M., Bain, P. A., Woloszynek, S., Painter, J. L., Bate, A., & Beam, A. L. (2022). Artificial intelligence based on machine learning in pharmacovigilance: A scoping review. *Drug Safety, 45*(5), 477-491. https://doi.org/10.1007/s40264-022-01171-4

Luo, Y., Thompson, W. K., Herr, T. M., Zeng, Z., Berendsen, M. A., Jonnalagadda, S. R., & Weng, C. (2017). Natural language processing for EHR-based pharmacovigilance: A structured review. *Drug Safety, 40*(11), 1075-1089. https://doi.org/10.1007/s40264-017-0558-6

Mockute, R., Desai, S., Perera, S., Assuncao, B., Danysz, K., Tetarenko, N., Gaddam, D., Abatemarco, D., Widdowson, M., Beauchamp, S., & Cicirello, S. (2019). Artificial intelligence within pharmacovigilance: A means to identify cognitive services and the framework for their validation. *Pharmaceutical Medicine, 33*(2), 109-120. https://doi.org/10.1007/s40290-019-00267-0

Murali, K., Kaur, S., Prakash, A., & Medhi, B. (2019). Artificial intelligence in pharmacovigilance: Practical utility. *Indian Journal of Pharmacology, 51*(6), 373-376. https://doi.org/10.4103/ijp.IJP_620_19

Salas, M., Petracek, J., Yalamanchili, P., Aimer, O., Kasthuril, D., Dhingra, S., Junaid, T., & Bostic, T. (2022). The use of artificial intelligence in pharmacovigilance: A systematic review of the literature. *Pharmaceutical Medicine, 36*(5), 295-306. https://doi.org/10.1007/s40290-022-00428-3

Schmider, J., Kumar, K., LaForest, C., Swankoski, B., Naim, K., & Caubel, P. M. (2019). Innovation in pharmacovigilance: Use of artificial intelligence in adverse event case processing. *Clinical Pharmacology & Therapeutics, 105*(4), 954-961. https://doi.org/10.1002/cpt.1223

U.S. Food and Drug Administration. (2025). *Considerations for the use of artificial intelligence to support regulatory decision-making for drug and biological products: Draft guidance for industry*. FDA.

World Health Organization. (2002). *The importance of pharmacovigilance: Safety monitoring of medicinal products*. WHO.

World Health Organization. (2021). *Ethics and governance of artificial intelligence for health: WHO guidance*. WHO.

Bate, A., & Luo, Y. (2022). Artificial intelligence and machine learning for safe medicines. *Drug Safety, 45*(5), 403-405. https://doi.org/10.1007/s40264-022-01160-7 (ScienceDirect)

Bate, A., Evans, S. J. W. (2009). Quantitative signal detection using spontaneous ADR reporting. *Pharmacoepidemiology and Drug Safety, 18*(6), 427-436. https://doi.org/10.1002/pds.1742 (ScienceDirect)

Caster, O., Juhlin, K., Watson, S., & Norén, G. N. (2014). Improved statistical signal detection in pharmacovigilance by combining multiple strength-of-evidence aspects in vigiRank. *Drug Safety, 37*(8), 617-628. https://doi.org/10.1007/s40264-014-0204-5 (ScienceDirect)

Cherkas, Y., Ide, J., & van Stekelenborg, J. (2022). Leveraging machine learning to facilitate individual case causality assessment of adverse drug reactions. *Drug Safety, 45*(6), 571-582. https://doi.org/10.1007/s40264-022-01182-5 (ScienceDirect)

Comfort, S., Perera, S., Hudson, Z., Dorrell, D., Meireis, S., Nagarajan, M., Ramakrishnan, C., & Fine, J. (2018). Sorting through the safety data haystack: Using machine learning to identify individual case safety reports in social-digital media. *Drug Safety, 41*(6), 579-590. https://doi.org/10.1007/s40264-017-0622-2 (ScienceDirect)

Desai, M. K. (2024). Artificial intelligence in pharmacovigilance. *Perspectives in Clinical Research*. https://pmc.ncbi.nlm.nih.gov/articles/PMC11318788/ (PMC)

Ménard, T., Barmaz, Y., Koneswarakantha, B., Bowling, R., & Popko, L. (2019). Enabling data-driven clinical quality assurance: Predicting adverse event reporting in clinical trials using machine learning. *Drug Safety, 42*, 1045-1053. (ScienceDirect)

Norén, G. N., Orre, R., Bate, A., & Edwards, I. R. (2007). Duplicate detection in adverse drug reaction surveillance. *Data Mining and Knowledge Discovery, 14*(3), 305-328. (ScienceDirect)

Painter, J. L., Kassekert, R., & Bate, A. (2023). An industry perspective on the use of machine learning in drug and vaccine safety. *Frontiers in Drug Safety and Regulation*. https://doi.org/10.3389/fdsfr.2023.1110498 (Springer Link)

Warner, J. (2025). Artificial intelligence: Applications in pharmacovigilance. *Pharmaceutical Medicine*. https://doi.org/10.1007/s40290-025-00561-2 (Springer Link)

Ward, I. R., Wang, L., Lu, J., Bennamoun, M., Dwivedi, G., & Sanfilippo, F. M. (2021). Explainable artificial intelligence for pharmacovigilance: What features are important

Zhao, Y., Yu, Y., Wang, H., Li, Y., Deng, Y., Jiang, G., & Luo, Y. (2022). Machine learning in causal inference: Application in pharmacovigilance. *Drug Safety, 45*(5), 459-476. https://doi.org/10.1007/s40264-022-01172-3 (ScienceDirect)

Cite this article: Shah D. Artificial Intelligence in the Pharmaceutical Industry: A Literature Review. J Pharm Pract Comm Med. 2026;12(4):228-33.